Henderson, D.C., Cagliero, E., Copeland, P.M., Louie, P.M., Borba, C.P., Fan, X., Freudenreich, O. and Goff, D.C. (2007) Elevated Hemoglobin A1c as a Possible Indicator of Diabetes Mellitus and Diabetic Ketoacidosis in Schizophrenia Patients Receiving Atypical Antipsychotics. Journal of Clinical Psychiatry, 68, 533-541. http://dx.doi.org/10.4088/JCP.v68n0407

has been cited by the following article:

• TITLE: Case Reports: Treatment-Resistant Schizophrenia with Severe Type 2 Diabetes Mellitus Treated with Clozapine

  AUTHORS: Junji Gon, Shinji Sakamoto, Manabu Takaki

  KEYWORDS: Clozapine, Treatment-Resistant Schizophrenia, Type 2 Diabetes Mellitus, Brief Assessment of Cognition in Schizophrenia Japanese Version

  JOURNAL NAME: Open Journal of Psychiatry, Vol.6 No.1, January 11, 2016

  ABSTRACT: Objective: Clozapine is regarded as the most effective drug for treatment of schizophrenia but has complex adverse effects associated with hyperglycemia and diabetes mellitus. Method: We report that clozapine was very effective to treat positive, negative, and cognitive symptoms and well tolerated to a treatment-resistant schizophrenia patient with severe type 2 diabetes mellitus (DM) under cautious blood-sugar monitoring. Results: Clozapine itself and discontinuation of other psychotropic and anticholinergic agents after switching may improve cognitive function and adherence to the treatment regimens for schizophrenia and DM. Conclusion: Clozapine can be administered to treatment-resistant schizophrenia patients even with severe DM with caution.